Eagle Pharmaceuticals (NASDAQ:EGRX) Research Coverage Started at StockNews.com

Stock analysts at StockNews.com started coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a report issued on Wednesday. The brokerage set a “hold” rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Stock Performance

Shares of EGRX stock opened at $4.27 on Wednesday. Eagle Pharmaceuticals has a 52-week low of $3.21 and a 52-week high of $15.91. The stock has a market cap of $55.45 million, a PE ratio of 3.62 and a beta of 0.53. The firm’s 50 day moving average price is $4.74 and its two-hundred day moving average price is $4.75.

Hedge Funds Weigh In On Eagle Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Cubist Systematic Strategies LLC bought a new position in Eagle Pharmaceuticals in the second quarter valued at approximately $145,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Eagle Pharmaceuticals in the second quarter worth $65,000. Perceptive Advisors LLC acquired a new stake in Eagle Pharmaceuticals in the second quarter worth $971,000. Mackenzie Financial Corp acquired a new stake in Eagle Pharmaceuticals in the second quarter worth $60,000. Finally, Fidelis Capital Partners LLC acquired a new stake in Eagle Pharmaceuticals in the second quarter worth $71,000. 85.36% of the stock is owned by institutional investors.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.